Cannabis Use Disorder, Healthy, Schizophrenia and Other Psychotic Disorders
Conditions
Brief summary
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
Detailed description
The overall goal of this protocol is to study synaptic density in two psychiatric disorders (namely schizophrenia and other psychotic disorders, and cannabis use disorder) with this exciting new PET tracer. Secondary outcomes will include electroencephalography (EEG). A battery of EEG paradigms assessing sensory, perceptual, and cognitive functions will also be administered. The primary dependent measures will be traditional event related potentials (ERPs; e.g. latency and amplitude) as well as time X frequency analysis (inter-trial coherence and spectral power).
Interventions
DRUG[11C]APP311
It has been shown that radiotracer \[11C\]APP311 (aka \[11C\]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
Sponsors
Yale University
National Institute on Drug Abuse (NIDA)
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Willing and able to give voluntary written informed consent * Male and Female subjects, age 18 to 65 years, inclusive
Exclusion criteria
* MRI metal exclusions and claustrophobia. * Education completed is less than 12 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Synaptic density in psychiatric disorders using SV2A receptor PET Imaging with [11C]APP311 | One test day (one time point). | To compare synaptic vesicle protein 2A (SV2A) density in two groups of subjects with psychiatric disorders (namely 'schizophrenia and other psychotic disorders', and 'cannabis use disorder') to that in healthy controls using the PET radiotracer 11C-APP311 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of Synaptic density with cognition and EEG | One test day (one time point). | To correlate SV2A density with concurrent measures of information processing such as cognitive performance on a neuropsychiatric battery and electroencephalographic (EEG) measures |
Countries
United States
Contacts
CONTACTAngerlyk Frytz, MD
Outcome results
None listed